Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update

Thursday, May 9, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- Reported Positive Results from Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis

ALDEYRA THERAPEUTICS, INC.

BALANCE SHEETS

(UNAUDITED)

March 31,

December 31,

2019

2018

ASSETS

Current assets:

Cash and cash equivalents 

$       5,297,555

$         3,357,472

Cash equivalent - Reverse Repurchase Agreements

39,000,000

$       44,000,000

Marketable securities

37,826,635

46,242,220

Prepaid expenses and other current assets

4,872,067

1,169,594

Total current assets 

86,996,257

94,769,286

Deferred offering costs

86,644

Debt issuance costs

538,038

Right-of-use assets

377,920

Fixed assets, net

215,908

235,225

Total assets

$     88,128,123

$       95,091,155

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$       4,013,362

$         3,051,678

Accrued expenses

5,257,071

5,421,498

Current portion of operating lease liabilities

221,112

Total current liabilities

9,491,545

8,473,176

Operating lease liabilities, long-term

156,808

Total liabilities

9,648,353

8,473,176

Commitments and contingencies (Notes 14 and 15)

Stockholders' equity:

Preferred stock, $0.001 par value, 15,000,000 shares authorized, none   issued and outstanding 

Common stock, voting, $0.001 par value; 150,000,000 authorized   and 26,910,355 and 26,244,435 shares issued and outstanding, respectively

26,910

26,244

Additional paid-in capital

232,605,244

225,136,127

Accumulated other comprehensive income (loss)

6,812

(9,224)

Accumulated deficit

(154,159,196)

(138,535,168)

Total stockholders' equity

78,479,770

86,617,979

Total liabilities and stockholders' equity

$     88,128,123

$       95,091,155

ALDEYRA THERAPEUTICS, INC.

STATEMENT OF OPERATIONS

(UNAUDITED)

Three Months Ended March 31,

2019

2018

Operating expenses:

Research and development

$       7,848,590

$         6,600,106

Acquired in-process research and development

6,597,551

General and administrative

2,985,038

1,891,303

Loss from operations

(17,431,179)

(8,491,409)

Other income (expense):

Interest income

499,140

122,390

Interest expense

(1,962)

(28,044)

Total other income (expense), net

497,178

94,346

Loss before income taxes

(16,934,001)

(8,397,063)

Income tax benefit

1,309,973

Net loss

$    (15,624,028)

$       (8,397,063)

Net loss per share - basic and diluted

$               (0.58)

$                (0.43)

Weighted average common shares outstanding - basic and diluted

27,053,842

19,366,790



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store